Monday, October 25, 2021

Moderna CEO says coronavirus vaccine won’t be ready for FDA till late November: FT

As late-stage trials progress—or not—COVID-19 vaccine timelines have grown clearer. And here’s another data point—Moderna, a leading player, doesn’t expect to be ready to file for an emergency use authorization until late November, its CEO said this week. 

Speaking at a Financial Times event, Moderna CEO Stéphane Bancel said it’ll be November 25 at the earliest before the company can seek an emergency nod. Under guidelines Moderna worked out with the agency, the biotech will compile two-month safety data for at least half of trial participants who have received their second doses. 

In the company’s phase 3 trial, the 15,000th participant received the second dose last Friday, Sept. 25, he said. That means it’ll be Nov. 25 at the earliest before the company can seek an EUA. 


Developing COVID-19 vaccines may not be enough: Turning vaccines into vaccinations

COVID-19 vaccines are being developed at a breakneck pace, but a broken supply chain could derail that momentum. What are the steps needed to help ensure the medical supply chain is up to the task?

Bancel’s comments come as President Donald Trump and others in his administration maintain a vaccine is just weeks away. Pfizer has said it expects early efficacy data in late October, but the big pharma’s CEO voiced concerns about politics entering the process in an open letter this week. 

Pfizer’s trial design could give that company a faster timeline to the FDA, Bancel said. Still, experts have urged Pfizer to hold off until it can review two-month safety data.

RELATED: Pfizer urged to hold off on coronavirus vaccine until late November

For a full approval and general distribution, Moderna is aiming for the spring, Bancel told FT.

At Tuesday’s presidential debate, moderator Chris Wallace asked Trump about administration health officials’ statements that it’ll be next summer before a COVID-19 vaccine is “generally available.” The president responded that he’s “spoken to the companies, and we can have it a lot sooner.”  

Aside from Moderna and Pfizer, AstraZeneca, Johnson & Johnson and Novavax are also in late-stage testing. The partnership between Sanofi and GSK recently started a phase 1/2 study with plans to file for approvals during the first half of 2021. 

RELATED: Trump, Biden spar over COVID-19 vaccines at debate. Will it help public trust in the process? 

AstraZeneca’s vaccine has started a “rolling review” in Europe even as its U.S. trial remains halted for an FDA safety investigation. J&J expects early doses of its vaccine to be available in early 2021, while Novavax’s CEO has said the company expects to file for approval in December. 

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...